Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

Switzerland’s Galderma today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...

Rare Cannabinoid Company, a leader in hemp-derived wellness products, is celebrating February Sleep Awareness Month with an exclusive Buy One, Get One 50% Off sale on all CBN ...

Valmet announced on December 18, 2024, that the Board of Directors of Valmet has decided to use the authorization granted by the Annual General Meeting held on March 21, 2024, to repurchase the ...

has approved Nemluvio® (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis.1 Nemluvio was granted Breakthrough Therapy Designation in ...

First, we have nemolizumab or NEMLUVIO, which was out-licensed ... a recommendation for approval for atopic dermatitis and prurigo nodularis. Lunsumio received approval for use third-line ...

In dealing with a lot of people who’ve had experience with nemolizumab in the clinical trials and then with prurigo nodularis in some cases overlapping ... Galderma receives U.S. FDA approval for ...